Emergence of Antibiotic-resistant Pseudomonas Aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1999 May 29

PMID 10348756

Citations 137

Authors

Y Carmeli

N Troillet

G M Eliopoulos

M H Samore

Affiliations

Soon will be listed here.

Abstract

Pseudomonas aeruginosa is a leading cause of nosocomial infections. The risk of emergence of antibiotic resistance may vary with different antibiotic treatments. To compare the risks of emergence of resistance associated with four antipseudomonal agents, ciprofloxacin, ceftazidime, imipenem, and piperacillin, we conducted a cohort study, assessing relative risks for emergence of resistant P. aeruginosa in patients treated with any of these drugs. A total of 271 patients (followed for 3,810 days) with infections due to P. aeruginosa were treated with the study agents. Resistance emerged in 28 patients (10.2%). Adjusted hazard ratios for the emergence of resistance were as follows: ceftazidime, 0.7 (P = 0.4); ciprofloxacin, 0.8 (P = 0.6); imipenem, 2.8 (P = 0.02); and piperacillin, 1.7 (P = 0.3). Hazard ratios for emergence of resistance to each individual agent associated with treatment with the same agent were as follows: ceftazidime, 0.8 (P = 0.7); ciprofloxacin, 9.2 (P = 0.04); imipenem, 44 (P = 0.001); and piperacillin, 5.2 (P = 0.01). We concluded that there were evident differences among antibiotics in the likelihood that their use would allow emergence of resistance in P. aeruginosa. Ceftazidime was associated with the lowest risk, and imipenem had the highest risk.

Citing Articles

The oral-lung microbiome dysbiosis: Unravelling its role in implications for chronic obstructive pulmonary disease (COPD) pathogenesis.

Mithradas N, Sudhakar U, Shanmugapriya K, Jeddy N, Ram S J Oral Maxillofac Pathol. 2025; 28(4):619-625.

PMID: 39949674 PMC: 11819631. DOI: 10.4103/jomfp.jomfp_277_24.

Phenotypes of a hypermutator lineage that emerged during prolonged mechanical ventilation in a patient without cystic fibrosis.

Nozick S, Ozer E, Medernach R, Kochan T, Kumar R, Mills J mSystems. 2023; 9(1):e0048423.

PMID: 38132670 PMC: 10804958. DOI: 10.1128/msystems.00484-23.

Biofilm formation: mechanistic insights and therapeutic targets.

Wang X, Liu M, Yu C, Li J, Zhou X Mol Biomed. 2023; 4(1):49.

PMID: 38097907 PMC: 10721784. DOI: 10.1186/s43556-023-00164-w.

Pattern of cephalosporin and carbapenem-resistant : a retrospective analysis.

AlBahrani S, Alqazih T, Aseeri A, Al Argan R, Alkhafaji D, Alrqyai N IJID Reg. 2023; 10:31-34.

PMID: 38076026 PMC: 10701576. DOI: 10.1016/j.ijregi.2023.11.012.

The Distribution, Drug Susceptibility, and Dynamic Trends of Infection in a Tertiary Hospital in China During 2016‒2022.

Li X, Liu X, Dong Z, Chai L, Liu Y, Qi J Infect Drug Resist. 2023; 16:3525-3533.

PMID: 37293538 PMC: 10246564. DOI: 10.2147/IDR.S408956.

References

Garner J, Jarvis W, Emori T, Horan T, Hughes J . CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16(3):128-40. DOI: 10.1016/0196-6553(88)90053-3. View

Milatovic D, Braveny I . Development of resistance during antibiotic therapy. Eur J Clin Microbiol. 1987; 6(3):234-44. DOI: 10.1007/BF02017607. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Quinn J, Dudek E, DiVincenzo C, Lucks D, Lerner S . Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986; 154(2):289-94. DOI: 10.1093/infdis/154.2.289. View

Miro E, Navarro F, March F, Sanchez F, Mirelis B . Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem. Eur J Clin Microbiol Infect Dis. 1995; 14(8):731-2. DOI: 10.1007/BF01690889. View

Harris A, Venkataraman L, DeGirolami P, Samore M, Carmeli Y . Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999; 28(5):1128-33. DOI: 10.1086/514760. View

DAgata E, Venkataraman L, DeGirolami P, Samore M . Molecular epidemiology of acquisition of ceftazidime-resistant gram-negative bacilli in a nonoutbreak setting. J Clin Microbiol. 1997; 35(10):2602-5. PMC: 230018. DOI: 10.1128/jcm.35.10.2602-2605.1997. View

Basustaoglu A, Gun H, Saracli M, Baysallar M, Haznedaroglu T . Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1995; 14(5):469-70. DOI: 10.1007/BF02114909. View

Fink M, Snydman D, Niederman M, Leeper Jr K, Johnson R, Heard S . Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994; 38(3):547-57. PMC: 284496. DOI: 10.1128/AAC.38.3.547. View

10.

Pechere J, VLADOIANU I . Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother. 1992; 29(5):563-73. DOI: 10.1093/jac/29.5.563. View

11.

Cometta A, Baumgartner J, Lew D, Zimmerli W, Pittet D, Chopart P . Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 1994; 38(6):1309-13. PMC: 188203. DOI: 10.1128/AAC.38.6.1309. View

12.

Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R . Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother. 1998; 42(11):2966-72. PMC: 105974. DOI: 10.1128/AAC.42.11.2966. View

13.

Carmeli Y, Troillet N, Karchmer A, Samore M . Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999; 159(10):1127-32. DOI: 10.1001/archinte.159.10.1127. View

14.

Troillet N, Samore M, Carmeli Y . Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 1997; 25(5):1094-8. DOI: 10.1086/516092. View